Technologies
PDF


WARF: P120329US01

SIgA Protein as Heath Supplement for Animals, Humans


INVENTORS -

Mark Cook, Jordan Sand

The Wisconsin Alumni Research Foundation (WARF) is seeking commercial partners interested in developing a commercial source of secretory immunoglobulin A to boost animal growth, fight gastrointestinal inflammation and treat other disorders related to deficiency.
OVERVIEWSecretory immunoglobulin A (sIgA) plays a critical role in immunity. The protein is found in breast milk and secreted in the gastrointestinal system during development and adulthood. Research suggests that animals and humans deprived of sIgA due to early weaning or health defect are at higher risk for disorders like celiac disease, skin allergy and inflammatory bowel disease.

At present there is no method for harvesting large quantities of sIgA. To be useful as a commercial health supplement, the protein must be directly obtained from an animal source at high purity and low cost.
THE INVENTIONUW–Madison researchers have developed a method for producing large quantities of animal- and human-grade sIgA. The protein is isolated from the intestinal fluid/lining of swine or cows, enriched and purified. The process is similar to how heparin, the common anticoagulant, is produced.
APPLICATIONS
  • New source of sIgA for health applications
  • Could be administered to animals to increase growth rate, improve feed efficiency and fight gastrointestinal inflammation
  • Could be administered to humans to correct sIgA deficiency or treat disease (e.g., atopic dermatitis, sepsis)
KEY BENEFITS
  • First known method of its kind
  • Yields large quantities of pure sIgA
  • Cost effective
  • Commercially viable
STAGE OF DEVELOPMENTThe researchers are optimizing the extraction process and have demonstrated increased animal weight gain and feed efficiencies at commercially relevant levels. Researchers have also demonstrated use in the prevention and treatment of dermatological lesion in rodents and dogs.
Contact Information
For current licensing status, please contact Emily Bauer at emily@warf.org or (608) 262-8638.
The WARF Advantage

WARF: A Leader in Technology Transfer Since 1925
Since its founding as a private, nonprofit affiliate of the University of Wisconsin–Madison, WARF has provided patent and licensing services to UW–Madison and worked with commercial partners to transform university research into products that benefit society. WARF intellectual property managers and licensing staff members are leaders in the field of university-based technology transfer. They are familiar with the intricacies of patenting, have worked with researchers in relevant disciplines, understand industries and markets, and have negotiated innovative licensing strategies to meet the individual needs of business clients.

The University of Wisconsin and WARF –
A Single Location to Accelerate Translational Development of New Drugs

UW–Madison has the integrative capabilities to complete many key components of the drug development cycle, from discovery through clinical trials. As one of the top research universities in the world, and one of the two best-funded universities for research in the country, UW–Madison offers state-of-the-art facilities unmatched by most public universities.

These include the Small Molecule Screening Facility at the UW Comprehensive Cancer Center; the Zeeh Pharmaceutical Experiment Station, which provides consulting and laboratory services for developing formulations and studying solubility, stability and more; the Waisman Clinical Biomanufacturing Facility; the Wisconsin Institute for Medical Research, which provides UW–Madison with a complete translational research facility; and the innovative, interdisciplinary Wisconsin Institutes for Discovery, home to the private, nonprofit Morgridge Institute for Research and its public twin, WID, part of the university's graduate school. The highly qualified experts at these facilities are ready to work with you to create a library of candidates for drug development.